Futuximab/Modotuximab

N/A

Report date: 2025/04/28 22:35:30

Base Information

Drug NameFutuximab/Modotuximab
Drug Alias NameDS-1024/DS-992Modotuximab+FutuximabModotuximab/FutuximabFutuximab+ModotuximabDS 992/DS 1024 +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumoursColorectal NeoplasmsSquamous Cell Carcinoma of Head and Neck +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesPoland +[14] 
CombinationsYes
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSymphogen A/S
China Registration ClassN/A

Develop Information

Active CompaniesInstitut De Recherches Internationales ServierServier (Beijing) Pharmaceutical R&D Co Ltd
Inactive CompaniesMerck KGaA, Darmstadt, GermanySymphogen A/S
Active IndicationsColorectal Neoplasms
Inactive IndicationsSolid tumoursSquamous Cell Carcinoma of Head and NeckCarcinoma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A